• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于细胞 SELEX 的一种新型 DNA 适体探针,可体外和体内识别去势抵抗性前列腺癌。

A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX.

机构信息

Department of Radiology, The Second Affiliated Hospital, Xi' an Jiaotong University, Xi'an, Shaanxi Province, 710004, People's Republic of China.

Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, 710032, People's Republic of China.

出版信息

Drug Des Devel Ther. 2024 Mar 18;18:859-870. doi: 10.2147/DDDT.S444988. eCollection 2024.

DOI:10.2147/DDDT.S444988
PMID:38524880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10959323/
Abstract

BACKGROUND

Early recognition of castration-resistant state is of significance for timely adjustment of treatment regimens and improvement of prognosis.

PURPOSE

This study aims to screen new aptamers CRda8 and CRda21 which recognize castration resistant prostate cancer (CRPC) cells with high affinity and specificity by SELEX technology.

METHODS

The enrichment of specific aptamer candidates was monitored by flow cytometric analysis. The affinity and specificity of aptamer candidates were evaluated by flow cytometry and immunofluorescence assay. MR imaging of CRda21-conjugated polyethylene glycol (PEG)-FeO nanoparticles to CRPC was further explored in vivo.

RESULTS

Both aptamers showed high specificity to target cells with dissociation constants in the nanomolar range, and did not recognize other tested cells. The staining of clinical tissue sections with fluorescent dye labeled aptamers showed that sections from CRPC exhibited stronger fluorescence while sections from benign prostatic hyperplasia and androgen dependent prostate cancer did not exhibit notable fluorescence. In vivo MRI demonstrated that CRda21-conjugated PEG-FeO had good affinity to CRPC and produced strong T2WI signal intensity reduction distinguished from peritumoral tissue.

CONCLUSION

The high affinity and specificity of CRda8 and CRda21 make the aptamer hold potential for early recognition of castration-resistant state and diagnosis of CRPC at the cellular level.

摘要

背景

早期识别去势抵抗状态对于及时调整治疗方案和改善预后具有重要意义。

目的

本研究旨在通过 SELEX 技术筛选出能够高亲和力和特异性识别去势抵抗性前列腺癌(CRPC)细胞的新型适体 CRda8 和 CRda21。

方法

通过流式细胞术分析监测特异性适体候选物的富集情况。通过流式细胞术和免疫荧光分析评估适体候选物的亲和力和特异性。进一步探讨了 CRda21 偶联聚乙二醇(PEG)-FeO 纳米颗粒对 CRPC 的磁共振成像。

结果

两种适体均表现出对靶细胞的高特异性,解离常数在纳摩尔范围内,且不识别其他测试细胞。用荧光染料标记的适体对临床组织切片进行染色显示,CRPC 组织切片显示出更强的荧光,而良性前列腺增生和雄激素依赖性前列腺癌组织切片则没有明显的荧光。体内 MRI 显示,CRda21 偶联的 PEG-FeO 对 CRPC 具有良好的亲和力,并产生强烈的 T2WI 信号强度降低,与肿瘤周围组织区分开来。

结论

CRda8 和 CRda21 的高亲和力和特异性使适体具有在细胞水平上早期识别去势抵抗状态和诊断 CRPC 的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/fa59f6e98755/DDDT-18-859-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/6d8f73a4d689/DDDT-18-859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/abbe5d358203/DDDT-18-859-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/e8c07e5ef3e4/DDDT-18-859-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/a624227840a5/DDDT-18-859-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/0fbef3a18e1f/DDDT-18-859-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/6dbcb2a78381/DDDT-18-859-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/ff7b3a91b549/DDDT-18-859-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/fa59f6e98755/DDDT-18-859-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/6d8f73a4d689/DDDT-18-859-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/abbe5d358203/DDDT-18-859-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/e8c07e5ef3e4/DDDT-18-859-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/a624227840a5/DDDT-18-859-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/0fbef3a18e1f/DDDT-18-859-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/6dbcb2a78381/DDDT-18-859-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/ff7b3a91b549/DDDT-18-859-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce19/10959323/fa59f6e98755/DDDT-18-859-g0008.jpg

相似文献

1
A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX.基于细胞 SELEX 的一种新型 DNA 适体探针,可体外和体内识别去势抵抗性前列腺癌。
Drug Des Devel Ther. 2024 Mar 18;18:859-870. doi: 10.2147/DDDT.S444988. eCollection 2024.
2
Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.通过细胞 SELEX 筛选识别 EpCAM 阳性前列腺癌的 DNA 适体及其用于体外和体内 MRI 的研究。
Drug Des Devel Ther. 2021 Sep 21;15:3985-3996. doi: 10.2147/DDDT.S322854. eCollection 2021.
3
DNA aptamer evolved by cell-SELEX for recognition of prostate cancer.通过细胞指数富集的配体系统进化技术筛选出的用于识别前列腺癌的DNA适配体。
PLoS One. 2014 Jun 23;9(6):e100243. doi: 10.1371/journal.pone.0100243. eCollection 2014.
4
Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA Enhances Gene Therapy in Castration-Resistant Prostate Cancer.适体功能化树枝状聚合物递送质粒编码长非编码 RNA 增强去势抵抗性前列腺癌的基因治疗。
Int J Nanomedicine. 2020 Dec 17;15:10305-10320. doi: 10.2147/IJN.S282107. eCollection 2020.
5
Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer.适体偶联多功能聚合物纳米粒子作为用于治疗去势抵抗性前列腺癌的 MRI 超灵敏靶向药物递送系统。
Biomed Res Int. 2020 Apr 25;2020:9186583. doi: 10.1155/2020/9186583. eCollection 2020.
6
An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.基于适体的乳腺癌分子分型探针。
Theranostics. 2018 Nov 10;8(20):5772-5783. doi: 10.7150/thno.28949. eCollection 2018.
7
Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging.用于转移性前列腺癌识别和组织成像的DNA适配体的筛选与表征
Oncotarget. 2016 Jun 14;7(24):36436-36446. doi: 10.18632/oncotarget.9262.
8
Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.通过RGD-PEG-DSPE/DOPA/CaP纳米颗粒共递送GRP78 siRNA和多西他赛用于治疗去势抵抗性前列腺癌。
Drug Des Devel Ther. 2019 Apr 29;13:1357-1372. doi: 10.2147/DDDT.S198400. eCollection 2019.
9
Cancer cell targeting using multiple aptamers conjugated on nanorods.使用缀合在纳米棒上的多种适配体进行癌细胞靶向
Anal Chem. 2008 Feb 1;80(3):567-72. doi: 10.1021/ac702322j. Epub 2008 Jan 1.
10
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.一种用于检测转移性去势抵抗性前列腺癌中雄激素受体剪接变体-7蛋白表达的新型免疫组织化学检测方法的分析验证和临床鉴定
Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

引用本文的文献

1
Use of Mesenchymal Stem Cell-Targeting 3WJ Nanoparticles and Reported Specific Delivery of Anti-miRNA 138 to Treat Osteoporosis.使用靶向间充质干细胞的3WJ纳米颗粒及报道的抗miRNA 138特异性递送治疗骨质疏松症。
ACS Omega. 2025 Mar 4;10(10):10633-10641. doi: 10.1021/acsomega.4c11505. eCollection 2025 Mar 18.

本文引用的文献

1
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.剖析雄激素剥夺疗法对晚期前列腺癌钙黏蛋白转换的影响:分子视角。
Oncol Res. 2023 Jan 12;30(3):137-155. doi: 10.32604/or.2022.026074. eCollection 2022.
2
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.PI-RADS v2.1 联合 PSAD 对临床显著前列腺癌的诊断价值。
Abdom Radiol (NY). 2022 Oct;47(10):3574-3582. doi: 10.1007/s00261-022-03592-4. Epub 2022 Jul 5.
4
Definition of Castrate Resistant Prostate Cancer: New Insights.去势抵抗性前列腺癌的定义:新见解
Biomedicines. 2022 Mar 17;10(3):689. doi: 10.3390/biomedicines10030689.
5
The role of MRI in prostate cancer: current and future directions.MRI 在前列腺癌中的作用:现状与未来方向。
MAGMA. 2022 Aug;35(4):503-521. doi: 10.1007/s10334-022-01006-6. Epub 2022 Mar 16.
6
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.原发性前列腺癌中预先存在的去势抵抗性前列腺癌细胞样细胞促进对激素治疗的抵抗。
Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17.
7
Metastatic Prostate Cancer: Treatment Options.转移性前列腺癌:治疗选择
Oncology. 2022;100(1):48-59. doi: 10.1159/000519861. Epub 2021 Nov 15.
8
Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles.体内磁性植入物引导索拉非尼经超顺磁固体脂质纳米粒肝递送。
J Colloid Interface Sci. 2022 Feb 15;608(Pt 1):239-254. doi: 10.1016/j.jcis.2021.09.174. Epub 2021 Sep 29.
9
Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.通过细胞 SELEX 筛选识别 EpCAM 阳性前列腺癌的 DNA 适体及其用于体外和体内 MRI 的研究。
Drug Des Devel Ther. 2021 Sep 21;15:3985-3996. doi: 10.2147/DDDT.S322854. eCollection 2021.
10
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.NCCN 指南解读:前列腺癌,第 1.2021 版。
J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.